Newsfeeds - Spark Newswire

1 minute read

Analysts Consider CRISPR Therapeutics’ Blood Disorder Trial Data Encouraging, Impressive

Today, 6:19 PM

CRISPR Therapeutics (NASDAQ: CRSP) presented results from its ongoing Phase 1 COBALT-LYM CTX130 (exa-cel) trial, an allogeneic CAR-T cell therapy targeting CD70 for solid tumors and certain hematologic malignancies.

BLUE

2 minute read

Analyst Ratings

Expert Ratings for Vertex Pharmaceuticals

By Benzinga Insights

Today, 6:19 PM

Over the past 3 months, 8 analysts have published their opinion on Vertex Pharmaceuticals (NASDAQ:VRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

VRTX

11 minute read

Vertex To Present Data Demonstrating Significant Benefits Of Long-Term And Early Treatment With CFTR Modulators At The European Cystic Fibrosis Conference

By Benzinga Newsdesk

Today, 6:19 PM

Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference - TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and

VRTX

7 minute read

Vertex Presents New Data From VX-880 Phase 1/2 Clinical Trial At The American Diabetes Association 82nd Scientific Sessions

By Benzinga Newsdesk

Today, 6:19 PM

Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes Association 82nd Scientific Sessions – Patient 1 showed blood glucose time-in-range change from 40.1% on 34.0

VRTX

1 minute read

Maxim Group Upgrades Vertex Pharmaceuticals to Buy, Announces $325 Price Target

By Benzinga Newsdesk

Today, 6:19 PM

Maxim Group analyst Jason McCarthy upgrades Vertex Pharmaceuticals (NASDAQ:VRTX) from Hold to Buy and announces $325 price target.

VRTX

3 minute read

The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton’s Partnered Epilepsy Drug, ASCO Conference Gets Underway And More

By Shanthi Rexaline

Today, 6:19 PM

Biotech stocks advanced in the week ended May 27, tracking the overall positive sentiment of the broader market. Notwithstanding the week's strength, the sector has been one of the worst performers for the year-to-date period.

ABBV

10 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For May 23, 2022

By Benzinga Insights

Today, 6:19 PM

ABBV

1 minute read

Catalyst Biosciences Stock More Than Doubles After Assets Sale To Vertex

By Vandana Singh

Today, 6:19 PM

Catalyst Biosciences Inc (NASDAQ:CBIO) has agreed to sell its portfolio of protease medicines that regulate complement to Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for $60…

BIIB

1 minute read

Pre-Market Outlook

Benzinga Pro’s Top 5 Stocks To Watch For Monday, May 23, 2022: NVDA, RDBX, CBIO, VRCA, CWH

By Benzinga Newsdesk

Today, 6:19 PM

Today's 5 Stock Ideas: NVIDIA (NVDA) - Will report quarterly results Wednesday after market close. Redbox (RDBX) - One of the most popular stocks among the retail trader group over the last couple weeks.

CBIO

2 minute read

Why This Analyst Has ‘Little Conviction’ On CRISPR’s Upcoming Trial Data

By Vandana Singh

Today, 6:19 PM

RBC Capital Markets says it remains on the sidelines given commercial uptake for CRISPR Therapeutics’ (NASDAQ: CRSP) sickle cell disease (SCD)/beta-thalassemia…

ALLO